ALG1001 Leads Allegro’s Progress in Retinal Diseases
Vicken Karageozian, Co-Founder & CTO for Allegro Ophthalmics, shares his company’s story and highlights the progress of their lead molecule, ALG1001, a lead program for several retinal diseases. This program offers a long duration of effect, the option of using combination therapy and treatment for patients who have plateaued or are no longer responding to treatment.
Vicken Karageozian, MD
Dr. Karageozian is the CTO and Co-Founder of Allegro Ophthalmics and has 22+ years of experience in ophthalmic drug development at Allergan, ISTA Pharmaceuticals, and Vitreoretinal Technologies.